Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavilermide Phase 3 in Dry Eye
NCT02634853Phase 3Completed
- Sponsor
- Mimetogen Pharmaceuticals
- Start
- Dec 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of tavilermide in dry eye syndrome (DED), sponsored by Mimetogen Pharmaceuticals. Started Dec 2015; status: completed.
02
Drugs
tavilermide
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT02634853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02634853.